Fungal infections of skin and nails of feet

H. Williams
DOI: https://doi.org/10.1136/BMJ.319.7216.1070A
1999-10-16
British Medical Journal
Abstract:Editor—The systematic review on topical treatment for fungal infections of the feet and the accompanying editorial by Finlay illustrate the difficulties encountered when the evidence shows that an alternative treatment is both more effective and more expensive.1,2 Finlay (a member of the advisory board of Novartis, which manufactures the more expensive allylamine treatment) believes that we should give our patients the most effective (and most expensive) treatment. Hart et al provide purchasers with a more balanced view by presenting the costs of treating patients with an azole initially followed by an allylamine against the likely costs of treating all patients with allylamines from the start.
What problem does this paper attempt to address?